Public Profile

Formycon AG

Formycon AG, a leading biopharmaceutical company headquartered in Germany, is renowned for its expertise in the development of biosimilars. Founded in 2002, the company has established a strong presence in Europe and beyond, focusing on innovative therapies that enhance patient care. With a commitment to quality and efficacy, Formycon AG offers a range of biosimilar products that stand out for their rigorous development processes and regulatory compliance. The company has achieved significant milestones, including successful partnerships and product launches that underscore its position in the competitive biopharmaceutical landscape. Recognised for its scientific excellence, Formycon AG continues to drive advancements in the industry, making substantial contributions to the accessibility of biologic treatments for patients worldwide.

DitchCarbon Score

How does Formycon AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

17

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Formycon AG's score of 17 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.

20%

Let us know if this data was useful to you

Formycon AG's reported carbon emissions

Formycon AG, headquartered in Germany, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete figures or defined goals, it is challenging to assess their current impact on climate change or their strategic approach to reducing carbon emissions. As the biopharmaceutical industry increasingly prioritises sustainability, Formycon AG's future commitments and actions in this area will be crucial for aligning with industry standards and addressing climate challenges effectively.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Formycon AG's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Formycon AG is in DE, which has a medium grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Formycon AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Xbrane Biopharma AB

SE
Education services (80)
Updated 2 days ago

Fresenius

DE
Medical, precision and optical instruments, watches and clocks (33)
Updated 3 days ago

Biogen

US
Research and development services (73)
Updated 2 days ago

Novartis

CH
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Pfizer

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Amgen

US
Chemicals nec
Updated about 7 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers